Lodo Therapeutics discovers and develops novel therapeutics. We apply advanced technologies to tap the vast collections of undiscovered molecules encoded in microbial DNA that we extract from the environment. These evolutionarily optimized leads include an enormous number of structurally diverse molecules with drug-like properties that have been largely inaccessible until now. Yet many of today’s most widely used pharmaceuticals were developed from compounds produced by the tiny fraction of microbes (< 1%) that could be readily cultured in the laboratory.
The Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML), along with advances in synthetic biology and automation. We use these tools to bypass culturing by first identifying and prioritizing the most promising of these drug-like molecules at the level of DNA, using in silico methods. Lodo’s proprietary process can increase speed and efficiency by orders of magnitude through enriching early leads and culling less-promising compounds sooner and at lower cost—only the compounds with the greatest promise are advanced to screening and lead optimization.
At Lodo, we are reinventing natural products drug discovery, which despite its successes had fallen out of favor. This reflected the difficulty of identifying novel compounds when only a limited number of cultured organisms was available for investigation, as well as the cumbersome and costly processes employed. We are able to discover new therapeutics for “undruggable” targets by accessing an entire universe of molecules whose biological properties have been optimized by billions of years of evolution. We see this as a historical opportunity to re-energize a critical segment of pharmaceutical R&D and reverse the declining productivity that is a concern to all who care about improving human health.
Lodo’s proprietary platform is based on the pioneering research of Dr. Sean Brady at the Rockefeller University. It integrates NGS, synthetic biology, automation and advanced computational tools such as AI/ML to identify and prioritize promising drug-like molecules directly from biosynthetic gene clusters (BGCs) encoded in environmental microbial DNA. By directly identifying promising BGCs, instead of culturing the organism, Lodo gains access to potential drugs made by the >99% of microbes that have not been readily cultured. This represents the largest source of molecularly diverse, drug-like molecules that has ever been available to researchers.
Lodo’s approach identifies entirely new classes of molecules that are biologically relevant and encompass vast chemical diversity, reflecting eons of microbial evolution. They engage human targets and modulate human biology. Many of these novel structures could not have been conceived using traditional chemical synthesis. Their combination of biological relevance and chemical diversity is key for discovering truly novel therapeutics with the potential to address “undruggable” disease targets.
Lodo’s evolutionarily optimized lead molecules frequently have better permeability and greater target affinity than those created by chemical synthesis, which further enhance their drug-like properties. Once found, they are easier to produce through their established biosynthetic pathways.
The Lodo technology platform can increase speed and efficiency, outpacing traditional approaches to environmentally sourced drug discovery. Lodo’s innovative platform is re-inventing and expanding the field to tap the largest reservoir of biologically relevant molecules with new drug potential.
Lodo is discovering and developing novel cancer and anti-infective therapeutics for our internal pipeline and initiating discovery programs in additional indications. Collaborating is key to unlocking the full potential of the Lodo platform. We are pursuing new partnerships with the many pharmaceutical and biotechnology companies who could benefit from our drug discovery engine.
Lodo Therapeutics is supported by distinguished life science investors and has major partnerships with the Bill and Melinda Gates Foundation and Genentech. The utility of Lodo’s technology platform has been demonstrated by the early success of the company’s work for these partners.
Lodo Therapeutics is an Accelerator Life Science Partners-backed entity headquartered in New York City at the Alexandria Center for Life Science.
Lodo Therapeutics Corp.
Eli Lilly and Company
ARCH Venture Partners
Vatera Healthcare Partners
Accelerator Life Science Partners
Alexandria Venture Investments & Alexandria LaunchLabs–NYC